Ocular Therapeutix to Present at Morgan Stanley 2014 Global
Ocular Therapeutix (Nasdaq: OCUL) today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Morgan Stanley 2014 Global Healthcare Conference.
The presentation will be held at the Grand Hyatt New York Hotel on Wednesday, September 10, 2014 at 9:45 am ET. The audio-only presentation will be accessible live on Ocular’s website at www.oculartherapeutix.com  in the Investors section and will be available for 60 days following the presentation. A copy of the investor presentation will also be made available in the Investor section.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.